A randomized controlled trial to evaluate the safety and efficacy of twice-weekly peginterferon alpha 2a [Pegasys] and ribavirin induction therapy for chronic hepatitis C in patients who are coinfected with HIV-1.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 27 Jun 2011 Biomarkers information updated
- 14 Jun 2011 Additional lead trial investigator (Shyamasundaran Kottilil) identified as reported by ClinicalTrials.gov.
- 18 Apr 2011 Results published in the AIDS.